This post is an attempt to present in a tabular format, information on the the currently available UK marketing authorisation routes for medicines. The information is by no means exhaustive and can be used as a starting point for further research.
This article answers some of the key legal and practical questions surrounding the grant of marketing authorisation for pharmaceuticals and medical devices in United Kingdom.
Marketing authorisations (MAs) granted since January 2014. Previous lists of granted licences are available on the National Archives website. A list of all of the marketing authorisations...
Marketing authorisations in the UK are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (MHRA) Submissions Portal.
This particular example perfectly highlights why Neither Holds Uk Marketing Authorisation is so captivating.
Gaining marketing authorisation in the UK is a particularly rigorous undertaking, particularly when developing treatments for rare diseases.Acting as your UK marketing authorisation holder following MHRA approval, which allows you to commercialise your new product.
This authorisation is based on data from five global randomised controlled phase 3 studies involving 6,263 treated with type 2 diabetes and different doses of the drug on its own or with other treatments including including metformin, SGLT2 inhibitors, sulphonylureas and insulin glargine.
The Marketing Authorization Application (MAA) is anchored on comprehensive evidence from the recently concluded 24-month Phase 3 LUCIDITY trial and two prior Phase 3 studies in patients with mild to moderate Alzheimer's Disease (AD).
The marketing authorisation, which marks the second indication for NEXPOVIO, is valid in all 27 member states of the EU as well as Iceland, Liechtenstein, Norway, and Northern Ireland.
The UKs Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Eli Lillys tirzepatide solution for injection in an alternative KwikPen presentation, for two indications: For the treatment of adults with insufficiently controlled type 2 diabetes...
